HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improve bile duct-targeted drug delivery and therapeutic efficacy for cholangiocarcinoma by cucurbitacin B loaded phospholipid complex modified with berberine hydrochloride.

Abstract
In present study, a novel phospholipid complex loaded cucurbitacin B modified with berberine hydrochloride (CUB-PLC-BER) was prepared by a simple solvent evaporation method with the aim of improving bile duct-targeted drug delivery and therapeutic efficacy for cholangiocarcinoma (CC). The complex's physicochemical properties were systemically investigated in terms of scanning electron microscopy (SEM), x-ray diffraction (XRD) and infrared absorption spectroscopy (IR). In vivo and in vitro antitumor studies, CUB-PLC-BER and the unmodified cucurbitacin B-phospholipid complex (CUB-PLC) presented stronger antitumor efficacy against human cholangiocarcinoma cells (QBC939 cells) than free cucurbitacin B (CUB), while phospholipids (PL) itself had no significant toxicity. Besides that, CUB-PLC showed the advantage over the free CUB and CUB-PLC-BER with regard to the inhibition of tumor growth in vivo antitumor study. Failure to establish the orthotopic CC model, the study attempted to measure the level of CUB in plasma and in bile to explore bile duct-targeted effect indirectly. In the pharmacokinetics study in rats, the average values of Cmax and AUC0-8h of CUB-PLC-BER group in rat bile were higher than those of CUB-PLC, while an opposite result was found in plasma. Meanwhile, the Cmax, AUC0-8h and AUC0-24h of CUB were the least both in plasma and in bile. The results indicated that the CUB-PLC-BER tended to provide a high and prolonged drug concentration to bile duct, and PL played a central role in internalizing CUB into cells to improve the water insoluble drug's permeability, which was of great benefit to enhance the bioavailability of CUB and improve therapeutic efficacy of CC. These results elucidated the potential of CUB-PLC-BER as drug delivery system for improving bile duct-targeted and therapeutic efficacy for CC.
AuthorsLing Cheng, Ping-hua Xu, Bao-de Shen, Gang Shen, Juan-juan Li, Ling Qiu, Chao-yong Liu, Hai-long Yuan, Jin Han
JournalInternational journal of pharmaceutics (Int J Pharm) Vol. 489 Issue 1-2 Pg. 148-57 (Jul 15 2015) ISSN: 1873-3476 [Electronic] Netherlands
PMID25882012 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier B.V. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Phospholipids
  • Triterpenes
  • cucurbitacin B
  • Berberine
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Berberine (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Bile (chemistry)
  • Bile Duct Neoplasms (drug therapy)
  • Bile Ducts (metabolism)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Cholangiocarcinoma (drug therapy)
  • Drug Delivery Systems
  • Humans
  • Male
  • Mice, Nude
  • Phospholipids (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Rats, Sprague-Dawley
  • Treatment Outcome
  • Triterpenes (administration & dosage, chemistry, pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: